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The presence of intralesional natural regulatory T cells, char-
acterized by the expression of Foxp3 mRNA, was analyzed in
patients with localized leishmaniasis due to Leishmania guy-
anensis infection that was unresponsive to treatment with
pentamidine isethionate. Foxp3mRNA levels were associated
with unresponsiveness to treatment among patients with a le-
sion duration of 1 month, but this association was not ob-
served among patients with a lesion duration of<1month. In
conclusion, high intralesional expression of Foxp3 might be
an indicator of poor response to treatment, depending on the
duration of lesions.
Infections with Leishmania species induce a spectrum of dis-
eases, from self-healing cutaneous leishmaniasis to mucosal and
visceral leishmaniasis. The clinical outcome depends on the in-
fective agent and on the specific immune response to Leishmania
antigens.
Given the great variety of epidemiological situations, the dif-
ferent factors influencing disease transmission, and the incom-
plete knowledge of the biology of the parasite and its vector and
reservoirs, disease control is difficult to achieve. Furthermore,
effective prevention is difficult to achieve, and current curative
therapy is costly, often poorly tolerated, and not always effective.
Failure of antileishmanial therapy (such as antimonials, pen-
tamidine, and amphotericin) is often due to drug resistance.
There is currently no markers of resistance to leishmanicidal
drugs, and the only method for monitoring resistance relies on
an in vitro amastigote/macrophage system [1].
It is fully accepted that the leishmanicidal effect of conven-
tional therapy (pentavalent antimony and pentamidine) for ex-
perimental visceral leishmaniasis requires T cells, interferon
(IFN)–, and interleukin (IL)–12 [2–5]. In addition, in a ran-
domized, controlled trial, the cure rate with antimonials treat-
ment was reported to be lower in HIV-infected patients with
visceral leishmaniasis than in non–HIV-infected patients [6],
suggesting that cellular immune responses play an important
role in unresponsiveness to treatment during human infection.
In this context, we have already demonstrated that high in-
tralesional IL-10mRNA expression is associated with unrespon-
siveness to treatment with pentamidine isethionate during the
early phases of infection with L. guyanensis (i.e., 30 days of
evolution) [7]. IL-10 might regulate the responses to chemo-
therapy by inhibiting IL-12 and/or IFN- production.
Among the populations of cells that can produce IL-10, the
recently described regulatory T (Treg) cells have been extensively
analyzed in the context of tolerance, autoimmunity, and infec-
tions [8, 9]. These cells specifically express the transcription fac-
tor Foxp3 [10]. During cutaneous infection with Leishmania
braziliensis, human Treg cells have been shown to accumulate at
the site of infection and contribute to the control of effector T
cell functions [11]. However, the mechanisms of such suppres-
sion are debatable. Indeed, although the cytokines they produce
(i.e., IL-10 and transforming growth factor [TGF]–) have been
described as suppressive, recent data have clearly shown that, in
both human and experimental infection, the IL-10 produced by
Treg cells is not necessary for the suppressive activity of these cells
[12–14].
In the present study, we investigated whether, in patients in-
fected with L. guyanensis, the presence of Treg cells, characterized
by the expression of Foxp3 mRNA, is associated with unrespon-
siveness to treatment.
Methods. Forty-eight patients (36 males and 12 females
who were 16–57 years old) with localized cutaneous leishmani-
asis due to L. guyanensis infection underwent precise clinical
examination of the lesions, including localization and enumer-
ation, before treatment with pentamidine isethionate (Penta-
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carinat; Rhone Poulenc), which was administrated at 4mg/kg in
2 intramuscular injections on days 1 and 3. All patients were
seronegative for HIV.
Samples from patients with localized cutaneous leishmaniasis
were collected on days 15–150 of lesion evolution. Eleven and 37
patients developed lesions for 1 and 1 month, respectively.
Informed consent was obtained from the patients, and the hu-
man experimentation guidelines of the Centre Hospitalier An-
drée Rosemon in Cayenne were followed in the conduct of this
research.
Parasitological diagnosis was done by collecting serous der-
mal fluid from the border of the lesion, using May-Grunwald-
Giemsa staining. Parasites isolates were determined to be L. guy-
anensis on the basis of isoenzyme polymorphism on parasite
culture.
Clinical evaluation after treatment (between 1 and 3 months)
showed that lesions of 37 of the 48 patients had regressed (group
1 patients, responsive to treatment), whereas lesions of 11 pa-
tients were unchanged or worsened (group 2 patients, unre-
sponsive to treatment). Of the 11 patients unresponsive to treat-
ment, 3 developed lesions for 1 month, and 8 developed
lesions for1 month. These patients were given a second treat-
ment with pentamidine isothionate at the same dose.
Punch biopsies (2-mm diameter) were done and total RNA
was isolated as described elsewhere [7], using the RNeasy Mini
Kit (Qiagen). First-strand cDNA synthesis was done on total
RNA by means of a first-strand cDNA synthesis kit (Superscript
III First-Strand Synthesis System; Invitrogen). Real-time poly-
merase chain reaction was performed using the 7300 Real-Time
System (Applied Biosystems). FAM-MGB–labeled primer/
probe sets for IFN- (Hs 00174143-m1), IL-10 (Hs00174086-
m1), Foxp3 (Hs 00203958-m1), and -actin (Hs 99999903-m1;
used as endogenous control) were from Applied Biosystems.
The relative quantification of products was determined by the
comparative threshold cycle (Ct) method, using the equation
2Ct. Expression of each gene of interest was normalized to the
expression of the -actin endogenous gene, and the results are
displayed as relative to the expression of the same gene in periph-
eral blood mononuclear cells. In some experiments, results are
expressed as the fold change of the specific gene in lesions of
patients unresponsive to treatment compared with patients re-
sponsive to treatment, which was defined as the reference. For
statistical analysis, we used the Wilcoxon rank sum test to com-
pare levels of cytokine mRNA within the different groups of
patients.
Results. We previously demonstrated that, during the first
month of lesion duration, high intralesional IL-10 mRNA ex-
pression is associated with unresponsiveness to treatment with
pentamidine isothionate [7]. To determine whether this IL-10
mRNA expression is associated with Foxp3 mRNA expression,
we analyzed samples from 11 patients with a lesion duration of
1 month. Three of these patients who were unresponsive to
treatment showed a high level of IL-10mRNAexpression (group
2, n  3) (figure 1A), confirming our previous result. However,
among patients with a lesion duration of1 month, equivalent
Foxp3 mRNA expression was detected in patients responsive
(group 1, n  8) or unresponsive (group 2, n  3) to treatment
(figure 1A). In addition, IFN- levels were not significantly dif-
ferent between both groups of patients (figure 1A).
Among patients with a lesion duration of1 month, levels of
Foxp3 mRNA transcripts were significantly higher in skin le-
sions of patients unresponsive to treatment (group 2, n  8)
than in those of patients responsive to treatment (group 1,
n  29) (P  .04) (figure 1B). The mean SD fold increase in
Foxp3 mRNA expression in patients from group 2 compared
with those fromgroup 1was 2.1  0.32 (figure 1C). In contrast,
levels of IL-10 mRNA were identical in patients responsive or
unresponsive to treatment (figure 1B and 1C), and levels of
IFN-mRNA transcripts were significantly lower in patients un-
responsive to treatment than in patients responsive to treatment
(P  .007) (figure 1B). Indeed, IFN-mRNA expression in pa-
tients from group 2 was 4-fold less than that in patients from
group 1 (figure 1C). IL-12p40 mRNA was not detectable in le-
sions of patients responsive or unresponsive to treatment (data
not shown).
Discussion. In this work, we have demonstrated that, in pa-
tients with a lesion duration of1 month, unresponsiveness to
treatment was associated with high levels of Foxp3mRNA at the
site of infection. Given that Foxp3 is a specific transcription fac-
tor of Treg cells [10], these results strongly suggest that unrespon-
siveness to treatment may be associated with a local suppression
of immune responses mediated by Treg cells.
Because a functional immune response is required for suc-
cessful treatment, we postulate that, in patients with a lesion
duration of 1 month, Treg cells may regulate IL-12 or IFN-
production and/or activity. Interestingly, although we were un-
able to detect IL-12p40 in the skin lesions of patients with a
lesion duration of1 month whether responsive or unrespon-
sive to treatment, we clearly demonstrated that IFN- tran-
scripts in lesions were lower among patients unresponsive to
treatment than among patients responsive to treatment. These
results suggest that intralesional Treg cells have suppressive func-
tions, as previously described in patients infected with L. bra-
ziliensis [11].
Because an IL-10–dependent suppressive role of Treg cells has
been reported, we analyzed IL-10 mRNA expression in patients
with a lesion duration of 1 month who were unresponsive to
treatment. No significant increase the level of IL-10mRNA tran-
scripts was demonstrated in these patients, compared with that
in patients responsive to treatment, suggesting that suppression
induced by Treg cells is independent of IL-10. This is in accor-
dance with the findings of previous reports showing that, in ei-
ther human or experimental cutaneous and visceral leishmani-
asis, the IL-10 produced by Foxp3 T cells is not associated with
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the immunosuppression described during Leishmania infection
[12–14].
TGF-, another cytokine produced by Treg cells, is also in-
volved in the immunosuppression mediated by Treg cells.
However, we were unable to detect TGF- production by
CD4CD25 T cells isolated from biopsy samples and stim-
ulated in vitro by L. guyanensis (data not shown). Nonethe-
less, we cannot exclude a role for this cytokine—particularly
its membrane form—in the immunosuppression induced by
Treg cells.
Immune responses induced by L. guyanensis have been shown
to be distinct during the early phase (1 month of lesion dura-
tion) versus the late phase (1 month of lesion duration). In-
deed, Th2 and Th1 responses predominate during the early and
late phases of infection, respectively [15]. In line with this, we
confirmed in the presentwork our previous results showing that,
among patients with a lesion duration of 1 month, high in-
tralesional IL-10mRNA expression is associated with unrespon-
siveness to treatment with pentamidine isothionate [7]. Thus, to
determine if IL-10–producing cells are Treg cells, Foxp3 mRNA
expression was analyzed in patients with a lesion duration of1
month. Although IL-10 mRNA expression was higher among
patients unresponsive to treatment than among to patients re-
sponsive to treatment, Foxp3 mRNA expression did not differ
between patients responsive or unresponsive to treatment. In-
terestingly, altogether these results confirm the dichotomy of the
2 phases (early versus late) of infection with L. guyanensis.
In conclusion, unresponsiveness to treatment is associated
with high IL-10 and not Foxp3mRNA expression at the site of
infection among patients with a lesion duration of1month.
In contrast, among patients with a lesion duration of 1
month, high Foxp3 but not IL-10 mRNA expression is asso-
ciated with unresponsiveness to treatment, although the exact
mechanisms involved in the suppression of Treg cells has not
yet been elucidated. However, these markers (i.e., high level
of Foxp3 or IL-10 mRNA expression) should be tools of pre-
dictive value for poor responsiveness to treatment (in addi-
tion to time of lesion duration) and could influence the ther-
apeutic scheme of treatment.
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